AstraZeneca Results Presentation Deck

Rare Disease Total Revenue ($m) Soliris 16% decrease at CER to $1,648m in H1 2023 1,200 1,000 800 600 400 200 ☐EM 0 EROW ■ Europe ■US Q2 Q3 2021 53 117 71 86 111 107 174 199 240 221 460 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2022 2023 99 63 84 83 115 104 91 88 86 216 190 179 183 184 608 591 574 523 491 448 445 Total Revenue ($m) Ultomiris 64% growth at CER to $1,364m in H1 2023 800 700 600 500 400 300 200 100 0 ■ EM EROW ■ Europe ■US Q2 a L - Q3 2021 5 56 69 167 214 220 Q4 Q1 Q2 Q3 Q4 2022 4 24 6 73 70 72 100 105 120 236 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 44 Q3 2021 Total Revenue shows the numbers reported by AstraZeneca following the acquisition of Alexion, which completed on 21 July 2021. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Q1 Q2 2023 4 4 77 90 122 134 315 365 381 13 17 98 110 159 152 434 Total Revenue ($m) 350 300 250 200 150 100 50 0 Strensiq 26% growth at CER to $562m in H1 2023 EM EROW ■ Europe ■US Q2 APPENDIX | H1 2023 Product Performance Q3 Q4 2021 st 4 6 15 20 16 20 124 173 Q1 9 19 19 161 Q2 1000 Q3 Q4 2022 Q1 Q2 2023 9 8 10 15 19 19 19 21 21 18 19 193 192 224 205 9 22 21 21 248

View entire presentation